Introduction, Plant Viruses From Pathogens to Biological Toolkit {#S1}
================================================================

Virology began in 1892 with D. Ivanovsky's paper describing the retention of virulence in leaf sap extracted from Crimean tobacco with mosaic leaf disease ([@B150]). Even though the extracted sap had been passed through bacteria-retaining filters, the filtrate retrained the ability to replicate within living plants ([@B19]). Later, [@B233] succeeded in precipitating the pathogen of tobacco mosaic disease, and experiments in 1936 by Bawden and Pirie revealed that this pathogen contained RNA and protein components ([@B17]; [@B16]). Further experiments in 1956 demonstrated that genetic information was stored in RNA molecules ([@B77]) and later the concept of self-assembly of RNA and coat protein (CP) into particles was established ([@B32]). This pathogen is known as tobacco mosaic virus (TMV) and is one of the prominent viruses in plant molecular pharming.

Tobacco mosaic virus belongs to the *Tobamovirus* genus with a positive sense, single-stranded genomic RNA (gRNA) with a 7-methylguanosine-5-triphosphate cap at the 5′ terminus ([@B66]) and a 3′ untranslated region (UTR) harboring a transfer RNA (tRNA)-like structure ([@B216]) as shown in [Figure 1A](#F1){ref-type="fig"}. It encodes a total of four proteins two of which are involved in RNA replication plus a movement protein (MP) and a CP ([@B91]). Inside the plant cell, the gRNA acts as a messenger RNA (mRNA) template for expressing a 126 kDa protein containing methyltransferase and helicase domains plus a 183 kDa (readthrough) protein containing a polymerase domain ([@B168]; [@B143]). The 126 kDa and the 183 kDa replication proteins bind to the terminal tRNA-like structure initiating transcription of complementary (negative-sense) template ([@B143]; [@B167]). This negative-sense RNA acts as a template for the synthesis of full-length positive strands and subgenomic RNAs containing MP and CP open reading frames (ORFs) ([@B106]). The MP is an RNA binding protein involved in cell-to-cell spreading of the virus ([@B44]; [@B38]) while the CP enhances the formation of replication complexes ([@B8]), long-distance movement ([@B194]; [@B101]), and viral particle assembly ([@B23]; [@B33]).

![Genomic organization and expression strategy of TMV and different strategies adapted to express recombinant protein or heterologous epitope using the full virus genome. **(A)** The positive single-stranded RNA genome has four separate ORF(s) with a 5′ terminus methylated nucleotide cap (m7G5'pppG) and 3′-terminus tRNA-like structure. The first two 5′ proximal ORF(s) encode 126 and 183 kDa readthrough proteins containing methyltransferase (MET), helicase (HEL), and polymerase (POL) domains which are involved in replication and transcription of the genome. ORF 3 and 4 are translated from separate subgenomic promoters and encode the 30 kDa movement protein (MP) and 17 kDa coat protein (CP) respectively. **(B)** Recombinant protein (RP) fused to the CP N-terminus using fusion peptide (FP) ([@B185]). **(C)** Recombinant epitope (RE) fused to the CP C-terminus using leaky UAG stop codon ([@B211]). **(D)** Coding region of RP cloned in place of the virus CP gene ([@B215]). **(E)** Coding region of RP downstream a subgenomic RNA promoter and placed between the MP and the CP genes ([@B58]). **(F)** Coding region of RP cloned downstream TMV subgenomic RNA promoter and placed between TMV MP gene and a heterogeneous CP (H-CP) gene. The latter was cloned into the TMV vector together with its heterogeneous subgenomic promoter from odontoglossum ringspot virus (ORSV) ([@B64]).](fpls-10-00803-g001){#F1}

During the 1980s, the field of plant molecular pharming was born ([@B78]) and various pharmaceuticals such as human hormones ([@B14]), antibodies ([@B100]), and vaccines ([@B219]), were produced using transgenic plants. Currently, several proteins manufactured in plants are commercialized such as bovine trypsin TrypZean expressed in maize and commercialized by Sigma-Aldrich (\#T3568, Sigma-Aldrich Corporation, United States), the 2006 USDA approved Newcastle disease virus for poultry produced in tobacco cell-suspension by Dow AgroSciences ([@B232]), and the 2012 FDA approved taliglucerase alfa (Elelyso^®^) for the management of type 1 Gaucher's disease produced in carrot cells by Protalix Biotherapeutics Inc. ([@B156]).

However, the generation and selection of stably transformed plants for heterologous protein expression is quite elaborate and time-consuming which lead scientists to research exploiting viruses for this purpose. Plant viruses such as TMV ([@B215]) and cowpea mosaic virus (CPMV) ([@B93]) were first adapted as full-virus vector then as a deconstructed-virus vector for recombinant protein expression. Later on, as we understood more of viral structure and capsid assembly, non-enveloped plant viruses were also manipulated for the generation of chimeric viral particles, nanoagents for carriage of various compounds and nanostructures building blocks. Furthermore, recently enveloped plant viruses, such as rhabdoviruses, have been recovered from agroinfiltrated cDNA, adding a viral particle with an amendable lipid envelope to the arsenal of available systems.

Plant Viruses in Recombinant Expression Technology, First-Generation Vectors {#S2}
============================================================================

Adopting plant viruses as vectors for transient expression offered many advantages over the transgenic system such as ability for application in various plant species ([@B97]), reduced gene-to-product time ([@B99]), and increased yields ([@B152]). At first, the host cells were infected with a full copy of plant virus (either DNA or *in vitro* transcribed RNA) into which the heterogenous sequence or gene of interest (GOI) was cloned. The first published virus-based vector was a gene-replacement model in which the GOI replaced the CP of brome mosaic virus (BMV) ([@B79]). However, lacking the CP, the recombinant virus was unable to spread, and infection was limited to inoculated cells. Further attempts followed using TMV-based vectors in which the GOI was inserted upstream the inherent CP gene and controlled by an additional subgenomic RNA promoter (the inherent CP subgenomic promoter was duplicated) ([@B57]). Still this design was unstable and homologous recombination resulted in the loss of inserted sequence and reversion to the wild-type virus ([@B58]). A third approach was to create a hybrid virus-vector containing different subgenomic promoter sequences from two tobamoviruses \[TMV and odontoglossum ringspot virus (ORSV)\]. This hybrid design resulted in a more stable vector that succeeded in the systemic expression of the recombinant protein ([@B64]). Other designs included fusing the recombinant protein to the TMV CP either at the C-terminal ([@B185]) or at the N-terminal downstream a leaky stop codon ([@B211]). [Figures 1B--F](#F1){ref-type="fig"}, show the above described modification approaches applied to TMV. [Table 1](#T1){ref-type="table"} lists a number of plant-made pharmaceutical proteins expressed using full-viral vectors.

###### 

Plant-made proteins expressed using full viral vectors.

  **Full virus strategy**                                                                                                                                                                                        
  --------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------ ---------
  Amyloid β protein (Aβ) fragments                                            Cucumber mosaic virus (CMV)                                                 Mechanical inoculation of *in vitro* transcribed RNA   [@B234]
  Cholera toxin b subunit                                                     Tobacco mosaic virus (TMV)                                                  Mechanical inoculation of *in vitro* transcribed RNA   [@B161]
  Dihydrofolate reductase (DHFR)                                              Cauliflower mosaic virus (CaMV)                                             Mechanical inoculation of naked DNA                    [@B28]
  Human anti-non- Hodgkin's lymphoma single-chain Fv (scFv) immunoglobulins   Hybrid tobacco mosaic virus (TMV) and odontoglossum ringspot virus (ORSV)   Mechanical inoculation of *in vitro* transcribed RNA   [@B157]
  Rice α-amylase                                                              Hybrid tobacco mosaic virus (TMV) and tomato mosaic virus (ToMV)            Mechanical inoculation of *in vitro* transcribed RNA   [@B128]
  Capsid protein VP1 of foot-and-mouth disease virus (FMDV)                   Bamboo mosaic virus (BaMV)                                                  Mechanical inoculation of naked DNA                    [@B249]

Plant Viruses in Recombinant Expression Technology, Second-Generation Vectors {#S3}
=============================================================================

Although viral vectors based on a full-genome demonstrated success in producing recombinant proteins, constructs with large inserts showed instability and low systemic spread ([@B204]; [@B9]). Together with biosafety concerns ([@B202]), these limitations lead to the development of second-generation vectors in which the virus genome was deconstructed into a replicon containing the essential viral genomic components for replication and gene expression while plant-infection was initiated exogenously. In this system, viral MP and/or CP genes were replaced by the recombinant GOI and the vector was introduced into plants as part of *Agrobacterium* delivered T-DNA ([@B90]), biolistic bombardment ([@B126]) or as chromosome-inserted replicon ([@B35]). Lacking the CP, the deconstructed-virus based vectors lacked the ability to encapsidate into viral particles, however, they retained the ability to replicate, transcribe, and translate as shown in [Figure 2](#F2){ref-type="fig"}.

![Diagrams showing different replicon-based expression systems. **(A)** Deconstructed monopartite RNA virus, TMV-based system, where the viral CP was substituted with the GOI under the control of a subgenomic promoter ([@B145]). **(B)** Deconstructed monopartite RNA virus, PVX-based system, where the viral CP and MP were substituted with the GOI under the control of a subgenomic promoter ([@B126]). **(C)** Deconstructed bipartite RNA plant virus, CPMV-based system, where the RNA-1 component supplies the viral RdRp, virus genome-linked protein, helicase, and protease, while the modified RNA-2 contains the GOI, replacing those of the viral MP and CP ([@B35]). **(A)** Described replicon design is capable of replication, cell-to-cell movement, transcription, and replication, while designs **(B,C)** are capable of all, but deficient in cell-to-cell movement. LB, left border; RB, right border of the T-DNA region.](fpls-10-00803-g002){#F2}

Among the monopartite RNA viruses, potato virus X (PVX) ([@B126]) and TMV ([@B145]) were first to be adopted as a deconstructed-virus vectors. Deconstructed-TMV based vectors were further commercially pursued by Icon Genetics as magnifection technology (trademarked as magnICON^®^) ([@B89]). The modifications included using a hybrid RdRP \[from turnip vein-clearing virus (TVCV)\] and *Arabidopsis* actin 2 (ACT2) as a promoter together with removal of cryptic thymine-rich intron sites plus selective introduction of introns ([@B154], [@B155]). Magnifection of hybrid TMV-based vectors yielded 4 g/kg of fresh weight tissue (FWT) of recombinant protein and 4.8 g/kg FWT of full immunoglobulin G (IgG) in less than 2 weeks ([@B20]).

Similarly, a deconstructed virus strategy was developed for the bipartite RNA1/RNA2 CPMV. Early research was based on maintaining an unmodified RNA-1 while introducing the recombinant gene to the RNA-2 construct. Recombinant expression was achieved using this methodology with both full-length and defective versions of RNA-2 coding plasmids ([@B146]). Surprisingly, vector systems based on deleted regions of RNA-2 (delRNA-2) achieved higher expression yields than those obtained with full-length RNA-2 vectors ([@B192]). Further experiments revealed that replication of delRNA-2 based molecules was not essential and high yields of recombinant protein expression was still achieved in the absence of RNA-1 ([@B192]). The modified delRNA-2-based mRNA was "hyper-translated" providing approximately 0.3 g/kg FWT of fully assembled monoclonal antibody within 6 days after agroinfection ([@B193]). [Table 2](#T2){ref-type="table"} lists a number of plant-made pharmaceutical proteins expressed using deconstructed-viral vectors.

###### 

Plant-made proteins expressed using deconstructed viral vectors.

  **Deconstructed virus strategy**                                                                                                                                                                                                                   
  ------------------------------------------------------ ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ---------
  Assembled full-size monoclonal antibody                Cowpea mosaic virus (CPMV)                                                                       Agroinfiltration of plasmids encoding viral vectors                                        [@B193]
  Assembled full-size monoclonal antibody                Combination of non-competing viral vectors tobacco mosaic virus (TMV) and potato virus X (PVX)   Agroinfiltration of pro-vector modules for *in planta* assembly                            [@B88]
  Green fluorescent protein (GFP)                        Cucumber mosaic virus (CMV)                                                                      Agroinfiltration of plasmids encoding viral vectors                                        [@B81]
  Hepatitis B core Norwalk virus capsid protein (NVCP)   Bean yellow dwarf virus (BeYDV)                                                                  Agroinfiltration of BeYDV-derived vector with viral replication-protein supplying vector   [@B104]
  Human growth hormone                                   Hybrid crucifer-infecting tobacco mosaic virus (cr-TMV) and turnip vein-clearing virus (TVCV)    Agroinfiltration of pro-vector modules for *in planta* assembly                            [@B87]

The CPMV RNA2-based expression system allowed an elegant extension in which the genome-integrated cDNA of RNA-2 was amplified using agroinfiltrated RNA-1 constructs or by crossing with RNA-1 transgenic plants ([@B35]). This method of an inducible-replicon system, or dormant viral cassette, was also applied with a tomato mosaic virus (ToMV) system in suspension-cultured plant cells ([@B63]). Other applications included development of dormant viral cassettes which can be activated at a custom-chosen stage using chemical inducers, such as ethanol ([@B260]), or via a Cre-*LoxP* recombination system ([@B224]).

Plant Viruses as Biological Particles, the Case of Non-Enveloped Viruses {#S4}
========================================================================

The plant viruses first exploited in biotechnology were non-enveloped and consist of CP subunits that have the ability to self-assemble into filamentous structures such as TMV ([@B6]) or hollow symmetric icosahedral structures such as CCMV ([@B257]) as shown in [Figures 3A,B](#F3){ref-type="fig"}.

![Representative plant viruses. **(A)** Image of tobacco mosaic virus ([@B164]) rendered on MS PowerPoint. **(B)** Image of cowpea chlorotic mottle virus ([@B207]) as obtained from VIPER ([@B37]).](fpls-10-00803-g003){#F3}

With better understanding of particle architecture, biophysical properties, and ability to manipulate their genomic material, these viruses also became exploited as virus-like particles (VLP), self-assembled structures devoid of any genomic material ([@B104]) and further developed as virus-based nanoparticles (VNP) ([@B208]). For instance, the detailed molecular structure knowledge of filamentous viruses such as TMV ([@B163]), PVX ([@B169]), TVCV ([@B136]), and PapMV ([@B252]) permitted their use for various applications such as vaccines ([@B205]; [@B173]; [@B220]), fluorescent markers ([@B253]), biocatalysts ([@B36]), nanoparticles for biologics purification ([@B239]), nanoparticles for *in vivo* imaging ([@B165]), and assembly units for memory devices ([@B225]), as shown in [Figure 4](#F4){ref-type="fig"}.

![Various filamentous plant viruses engineered for different biological applications.](fpls-10-00803-g004){#F4}

Non-enveloped plant viruses have been engineered in three different ways: modification of the outer capsid (whether through genetic manipulation, chemical modification of capsid's amino acids moieties, or through a combination of both), incorporation of heterologous cargo in the inner cavity, or particle integration into multivalent structures. [Table 3](#T3){ref-type="table"} provides examples of some current VNP that are being developed as agents used in gene delivery ([@B10]), chemotherapy ([@B196]), immunotherapy ([@B231]), vaccines ([@B175]), and plant virus-assisted sensors (reviewed in [@B67]).

###### 

List of some of the non-enveloped plant viruses that have been produced for VLP or VNP applications.

  ***Utilizing the exterior surface of viral particles (VLPs as scaffolds for peptide/epitope presentation)***                                                                                                                           
  -------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------- ----------------
  Alfalfa mosaic virus (AMV)                                                                                     Icosahedral           Plant-produced chimaeric VLP as vaccine for rabies virus and human immunodeficiency virus.        [@B255]
  Cowpea chlorotic mottle virus                                                                                  Icosahedral           Genetic manipulation and chemical modification for multivalent presentation of ligands            [@B86]
  Cowpea mosaic virus                                                                                            Icosahedral           Plant-produced chimaeric virus vaccine for human rhinovirus 14 and human immunodeficiency virus   [@B176]
  Papaya mosaic virus                                                                                            Rod-Shaped            *E. coli* produced VLP as chimaeric viral vaccine for influenza virus.                            [@B182]
  Potato virus X                                                                                                 Rod-Shaped            Plant-produced chimaeric virus vaccine for hepatitis C virus.                                     [@B227]
  Red clover necrotic mosaic virus                                                                               Icosahedral           Plant-produced VLP developed for targeted drug delivery.                                          [@B147]
  Tobacco mosaic virus                                                                                           Rod-Shaped            Plant-produced chimaeric virus vaccine for influenza virus.                                       [@B173]
  Turnip yellow mosaic virus                                                                                     Icosahedral           Plant-produced VLP developed as a biological probe.                                               [@B12]
                                                                                                                                                                                                                                         
  ***Utilizing the inner cavity of the virus***                                                                                                                                                                                          
                                                                                                                                                                                                                                         
  **Virus**                                                                                                      **Viral structure**   **Note**                                                                                          **References**
                                                                                                                                                                                                                                         
  Brome mosaic virus                                                                                             Icosahedral           Plant-produced VLP developed for encapsulation of organic chromophore.                            [@B116]
  Cowpea chlorotic mottle virus                                                                                  Icosahedral           *E. coli* produced VLP developed for encapsulation of polymers.                                   [@B65]
  Cowpea mosaic virus                                                                                            Icosahedral           Plant-produced VLP developed for encapsulation of metals.                                         [@B5]
  Hibiscus chlorotic ringspot virus                                                                              Icosahedral           Plant-produced VLP developed for drug delivery.                                                   [@B181]
  Tobacco mosaic virus                                                                                           Rod-Shaped            Plant-produced VLP developed for drug delivery.                                                   [@B54]

Production of plant virus based VLPs as vaccines received the attention since the early 1990 ([@B229]). Plant RNA viruses such as TMV ([@B127]), CPMV ([@B158]), CMV ([@B166]), plum pox potyvirus (PPV) ([@B72]), potato virus X (PVX) ([@B144]), and tomato bushy stunt virus (TBSV) ([@B112]) have been adapted for the production of vaccines and tested in various animal models. Studies conducted on the biodistribution and clearance of TMV ([@B29]), PVX and tomato bushy stunt virus (TBSV) ([@B22]) in animal models showed no VLP induced pathological damage. Plant viruses are not pathogenic to mammals but are recognized by the pathogen associated molecular pattern (PAMP) receptors of the innate immune system ([@B1]). They were shown to elicit a humoral response when administered by parenteral ([@B26]) or mucosal routes ([@B25]) and a cell mediated response ([@B254]; [@B121]). For instance, PapMV-CP-M2e VLP can induced murine anti-M2e antibodies that recognized influenza-infected cells and provided 100% protection ([@B59]) without any PapMV VLP induced cellular toxicity ([@B183]).

The production of plant virus based VLP(s) were not limited to plants, and a variety of heterologous systems such as insect cells ([@B133]), yeast ([@B30]) or *Escherichia coli* ([@B59]) have been employed to produce recombinant potato leafroll virus (PLRV), CCMV, and PapMV CP that assemble into viral particles indistinguishable from their plant produced counterparts. Nevertheless, plant-produced VLPs remain the most economical choice, as plant production is scalable and cost-effective with production costs lower than those in *E. coli* or eukaryotic-based systems ([@B129]; [@B226]), and has substantial safety advantage compared to mammalian-cells produced alternatives ([@B151]).

Toward Enveloped Virus Like Particles {#S5}
=====================================

In the last decade, VLPs have been extensively developed as recombinant vaccines in different systems whether in plants or mammalian ([@B206]), insects ([@B140]), yeast ([@B2]), and *E. coli* ([@B73]). They have proven to be immunogenic and few are currently available on the market such as Engerix^®^ \[for hepatitis B virus (HBV)\] ([@B120]), and Cervarix^®^ \[for human papillomavirus (HPV)\] ([@B214]), produced by GlaxoSmithKline, or their respective equivalents Recombivax HB^®^ ([@B230]), and Gardasil^®^ ([@B222]) produced by Merck.

Nevertheless, producing VLPs whether through genetic fusion or chemical conjugation remains challenging, especially for complex multimeric antigens ([@B111]; [@B21]), full length glycoproteins that adopt different conformations ([@B131]; [@B53]), large epitopes ([@B239]), or have termini that are involved in protein folding ([@B172]) and might interrupt the capsid synchronized assembly ([@B261]; [@B186]), while post-expression chemical conjugation has the drawback of further increasing downstream processing costs ([@B31]; [@B246]; [@B189]; [@B34]). Furthermore, chimeric VLPs expressing recombinant peptides were found to induce reduced neutralizing antibodies titre when compared to the full domain vaccines ([@B84]). Even among plant-virus based VLP(s), for instance, alfalfa mosaic virus-based *Plasmodium falciparum* Pfs25 VLP, although it was shown to induce *P. falciparum* blocking antibodies in mice ([@B114]), in Phase I clinical trial it was shown to provide a low protection level ([@B41]).

In line with those difficulties and limitations, and considering that some of these are not encountered with enveloped VLPs (eVLPs), there has been a growing trend toward the use of eVLPs as production platform ([@B85]). In this system, structural viral proteins are expressed and incorporated into host membranes released as particles. The envelope provides the flexibility for integration of complete envelope-proteins and glycoproteins resembling the native virus ([@B248]; [@B15]; [@B138]). Along this idea attempts have been made to produce various eVLPs for vaccine purposes, e.g., against influenza virus (production of eVLPs in insect cells expressing influenza virus structural proteins) ([@B122]), HIV (based on virosome, *in vitro* associated/spiked with an HIV1 gp41-derived peptide) ([@B142]) and breast cancer (based on *in vitro* association of antigenic peptides to synthesized phospholipid membranes) ([@B245]).

Influenza eVLPs have been produced from the co-expression of the two major antigenic envelope proteins hemagglutinin (HA) and neuraminidase (NA) plus matrix 1 (M1) ([@B177]) or from the co-expression of HA and M1 to enable budding ([@B82]). Most of these attempts have been performed in animal cell systems, but recently plants have also been used as platform for producing eVLPs against avian H5N1 Influenza ([@B135]). HA-based influenza VLPs were found to be budding from the plasma membrane of plant cells expressing HA only, without the need of further viral proteins ([@B56]), due to the absence of glycoprotein sialylation in plants ([@B203]). Moreover, and importantly, these plant-produced HA based eVLP vaccines were found to elicit durable and cross-reactive T cell responses and are currently undergoing clinical trials by Medicago ([@B134]). These findings support and strengthen the development and exploitation of enveloped plant virus-based vector systems, amenable for genetic manipulation, in plant molecular pharming. Few plant viruses exist that have a naturally occurring envelope. They classify within the orders *Bunyavirales* and *Mononegavirales*, of which the family *Rhabdoviridae*, and have a negative strand RNA genome ([@B125]). Considering that monopartite rhabdoviruses are easier to handle and a reverse genetics system has recently been established for a plant infecting rhabdovirus, they present the most attractive platform for development of pseudotyped viral-vaccines upon which their inherent envelope will provide the needed flexibility to incorporate large and complex antigens.

Plant Viruses as Biological Particles, the Case of Inherently Enveloped Viruses -- Rhabdoviruses as an Example {#S6}
==============================================================================================================

The *Rhabdoviridae* family contains an ecologically diverse group of viruses infecting hosts from a wide plethora of aquatic and terrestrial vertebrates and plants ([@B130]); rhabdoviruses from different kingdoms are listed [Table 4](#T4){ref-type="table"}. Plant rhabdoviruses, like all other viruses of the *Rhabdoviridae* family are enveloped, negative-sense RNA viruses ([@B109]). They have a bacilliform shape defined by two major structural components: an outer envelope made of the host lipid bilayer embedded with surface projections of the virus glycoprotein and a tightly coiled internal nucleocapsid composed of genomic RNA (gRNA) together nucleoprotein, phosphoprotein, and the polymerase protein ([@B247]) ([Figure 5](#F5){ref-type="fig"}, traditionally, plant rhabdoviruses were divided into *Cytorhabdovirus* or *Nucleorhabdovirus* genera, depending on the virus propagation sites within the cell while recently two new genera *Dichorhavirus* and *Varicosavirus*, with bipartite genomes, were added ([@B62]; [@B243]).

###### 

List of some rhabdoviruses including plant *Cytorhabdoviruses* and *Nucleorhabdoviruses* together with their host, host class, and vectors.

  ***Plant Rhabdoviruses***                                                                                                          
  --------------------------------------- ---------------------------------------- ---------------------- -------------------------- ---------
  Barley yellow striate mosaic virus      *Hordeum vulgare* and*Triticum durum*    Monocotyledonous       *Laodelphax striatellus*   [@B48]
  Lettuce necrotic yellows virus          *Lactuca sativa*                         Dicotyledonous         *Hyperomyzus lactucae*     [@B210]
                                                                                                                                     
  **Nucleorhabdovirus**                                                                                                              
                                                                                                                                     
  Cereal chlorotic mottle virus           *Zea mays*                               Monocotyledonous       *Nesoclutha pallida*       [@B94]
  Sonchus yellow net virus                *Sonchus oleraceus* and*Bidens pilosa*   Dicotyledonous         *Aphis coreopsidis*        [@B43]
                                                                                                                                     
  ***Animal Rhabdoviruses***                                                                                                         
                                                                                                                                     
  **Vesiculovirus**                                                                                                                  
                                                                                                                                     
  **Virus**                               **Animal host**                          **Vector**             **References**             
                                                                                                                                     
  Vesicular stomatitis Indiana virus      Livestock                                *Lutzomyia shannoni*   [@B217]                    
  Vesicular stomatitis New Jersey virus   Livestock                                *Simulium vittatum*    [@B47]                     
                                                                                                                                     
  **Lyssavirus**                                                                                                                     
                                                                                                                                     
  Rabies virus                            Broad host range                         *Vamplire bats*        [@B160]                    
  Duvenhage virus                         Broad host range                         *Insectivorous bats*   [@B221]                    
                                                                                                                                     
  ***Fish Rhabdoviruses***                                                                                                           
                                                                                                                                     
  **Virus**                               **Fish host**                            **Vector**             **References**             
                                                                                                                                     
  Snakehead rhabdovirus                   *Ophicephalus striatus*                  *--*                   [@B3]                      
  Rhabdovirus of penaeid shrimp           *Penaeus stylirostris*                   *--*                   [@B149]                    

![LNYV bullet-shape structure and its genomic RNA organization, replication and transcription strategy. **(A)** Diagram representing an LNYV particle showing the transmembrane glycoprotein, lipid bilayer, matrix protein, and genomic RNA together with the nucleoprotein forming the ribonucleoprotein coil. **(B)** LNYV gRNA (negative-sense) showing the 3′ *leader*, the N, P, 4b, M, G, and L genes, the 5′ *trailer* (sequential genes separated by a gene junction) and the transcription gradient. Genomic RNA is first replicated into agRNA (positive-sense), which is used as template for the production of (accumulating amounts of) progeny gRNA (negative-sense). **(C)** Legend of panel **(B)**.](fpls-10-00803-g005){#F5}

Many of the plant rhabdoviruses are transmitted by arthropods in a persistent propagative way in which the virus enters and replicates within the insect before transmission ([@B213]; [@B52]; [@B179]) while dichorhaviruses are transmitted by mites ([@B61]) and varicosaviruses by soil-borne fungi ([@B137]). Their spread is correlated with that of the vector ([@B213]), and no seed transmission has been reported. They infect both monocotyledonous ([@B49]) and dicotyledonous ([@B195]) plants, harming agricultural production ([@B40]; [@B71]). The typical symptoms of viral infection are necrosis, mosaic mottling of leaf tissue, and vein clearing ([@B108]).

Plant rhabdovirus gRNA encodes the rhabdoviruses canonical genes: Nucleoprotein (N), Phosphoprotein (P), Matrix (M), Glycoprotein (G), and Large Polymerase (L) ([@B110]), in addition to accessory genes ([@B235]) such as those coding for a cell-to-cell MP such as the 4b gene in lettuce necrotic yellow virus (LNYV) ([@B60]), gene 3 of rice yellow stunt rhabdovirus (RYSV) ([@B103]). Furthermore, the gRNA is flanked by UTRs termed 3′ *leader* and 5′ *trailer* ([@B80]) ([Figure 5B](#F5){ref-type="fig"}). The *leader* and *trailer* sequences are partially complementary and contain *cis*-acting signals involved in transcription and replication ([@B262]; [@B42]; [@B237]) while short intergenic sequences regulate mRNA synthesis and sequential transcription of the canonical genes ([@B241]; [@B11]).

Rhabdoviruses Transcription {#S6.SS1}
---------------------------

Theoretical models that explain rhabdovirus transcription and replication were built upon experiments on mammalian rhabdoviruses, and one of the most well studied is Vesicular Stomatitis virus (VSV) ([@B69]; [@B240]). The ribonucleoprotein (RNP) unit, consisting of viral RNA associated with the N, L, and P proteins, acts as the template for viral transcription and replication ([@B250], [@B251]; [@B119]). Virion-associated L protein transcribes the NC into mRNA of distinct proteins ([@B162]; [@B223]). The transcription direction and gradient follow the order of genes in the virus genome and are controlled by the untranslated 3′ -- *leader* sequence ([@B68]) and the non-translated inter-genomic regions respectively as shown in [Figure 5B](#F5){ref-type="fig"} ([@B13]; [@B74]). Transcription of the viral genes results in the generation of monocistronic 5′-capped and polyadenylated mRNAs.

Rhabdoviruses Replication {#S6.SS2}
-------------------------

Later during the infection, the N-P complex inhibits transcription and switches the function of the L protein from that of transcription to replication ([@B132]; [@B95]). First, the gRNA is replicated into an antigenomic sense RNA (agRNA) template, which is full positive-sense RNA without a cap and poly (A) tail and is encapsidated by the N protein ([@B7]; [@B258]). Later, agRNA functions as a template for progeny negative-sense gRNA ([@B4]; [@B107]). With the progeny gRNA assembled as RNP, the M protein converts the extended helical RNP into a condensed form ([@B118]), resulting in the bullet-shape morphology of rhabdoviruses ([@B159]). Finally, the G protein tail is incorporated into the assembled M-RNP complex, aiding the budding of progeny virus particles ([@B244]; [@B197]).

Recovery of Rhabdoviruses From cDNA {#S6.SS3}
-----------------------------------

Initial attempts to generate rhabdoviruses from cDNA were based on mammalian rhabdoviruses. Research on VSV revealed that genomic RNA must be encapsidated with the viral N protein to be a functional template for RNA-dependent RNA polymerase ([@B70]). This discovery was followed by a set of experiments that enabled the first rescue (reverse genetics system) of VSV defective interfering (DI) particles from cells co-transfected with the five canonical proteins ([@B170], [@B171]). Research on rabies virus (RABV) demonstrated the expression of a reporter gene cloned between the viral 3′ and 5′ termini in cells co-transfected with plasmids encoding for the three helper proteins N, P, and L ([@B50]). This finding was followed by the recovery of infectious, enveloped rabies virus particles from cDNA ([@B201]). Similarly, this strategy was subsequently used to rescue other vertebrate rhabdoviruses, such as VSV ([@B242]), Snakehead rhabdovirus (SHRV) ([@B113]), infectious haematopoietic necrosis virus (IIHNV) ([@B24]), and haemorrhagic septicaemia virus (VHSV) ([@B123]).

Similar attempts to reconstitute a plant rhabdovirus started at Jackson's laboratory, where *N. benthamiana* cellulose-digested protoplasts were found to be suitable for studying sonchus yellow net virus (SYNV) replication ([@B115]). However, the real challenge was the co-delivery of all plasmids needed for the recovery of recombinant viruses into a single cell. This difficulty was circumvented by using *Agrobacterium* infiltration to co-deliver vectors expressing SYNV helper proteins into *N. benthamiana* leaves ([@B92]). In 2013, the same group demonstrated the success of the first plant rhabdovirus SYNV minireplicon (MR) strategy ([@B83]). Plasmids harboring a positive-sense MR cassette containing two sequentially cloned reporter genes between the SYNV 3′ and 5′ termini together with SYNV helper proteins were co-infiltrated into *N. benthamiana*. The fluorescence signal was detected in 5--6 days post-infiltration and was restricted to single cells only. This promising success culminated in 2015 when infectious SYNV was recovered from the upper leaves of *N. benthamiana* plants agroinfiltrated with four plasmids harboring positive-sense SYNV cDNA together with helper protein plasmids ([@B238]).

Animal Rhabdoviruses as a Potential Model for Plant Rhabdoviruses in Plant Molecular Pharming {#S6.SS4}
---------------------------------------------------------------------------------------------

As mentioned earlier, mammalian rhabdoviruses, and in particular vesicular stomatitis virus (VSV), remains the prototype for reverse engineering and molecular adaptation of rhabdoviruses. Like all other rhabdoviruses it has the canonical N, P, M, G, and L genes in a negative sense single stranded RNA genome ([Figure 6A](#F6){ref-type="fig"}). VSV was successfully rescued from cDNA in 1995 ([@B242]) and in 1996 it was first engineered to express a reporter gene placed between those of the viral glycoprotein and the polymerase ([@B199]). Later in the same year, recombinant VSV (rVSV) was successfully produced incorporating a foreign protein, in addition to the VSV inherent glycoprotein, in viral envelope ([@B198]). In these recombinant VSV particles, two designs were considered. The first was with the full foreign protein incorporated into the VSV envelope ([Figure 6B](#F6){ref-type="fig"}) while the second was the exoplasmic domain of the foreign protein fused upstream of the transmembrane domain and the cytoplasmic tail of the VSV glycoprotein ([Figure 6C](#F6){ref-type="fig"}). Furthermore, in 1997, recombinant VSV lacking its inherent glycoprotein and expressing CD4 receptor to infect and kill HIV-1 infected T-cells was successfully rescued ([@B200]) ([Figure 6D](#F6){ref-type="fig"}).

![A schematic representation of wild type VSV and recombinant VSV designs. **(A)** 3′ to 5′ negative-strand genomic RNA organization of wild type VSV. **(B)** Recombinant VSV (rVSV) with foreign protein inserted between the VSV G and L genes. **(C)** rVSV with foreign protein fused to the inherent VSV glycoprotein. **(D)** Recombinant VSVΔG with foreign protein replacing the inherent VSV glycoprotein. **(E)** rVSV with foreign protein gene inserted upstream of the VSV N protein. **(F)** rVSV with the gene for foreign protein inserted upstream of the VSV N protein and with truncated VSV glycoprotein. *le*, leader; *tr*, trailer; insP, gene for inserted protein; Gtrc, truncated glycoprotein.](fpls-10-00803-g006){#F6}

The ability to rescue VSV without its inherent G protein (VSVΔG) gave the opportunity to generate safer non-propagating VSV based vaccines ([@B184]). Moreover, further attenuation strategies based on malleability of the rhabdovirus genome, strategies such as decreasing the expression level of viral genes by manipulating their position down the expression gradient ([@B76]) or by G gene truncations and N gene translocations ([@B45]) were also considered. For instance, inserting the foreign gene upstream of the VSV N gene ([Figure 6E](#F6){ref-type="fig"}), or inserting the foreign gene upstream the N gene while relocating the N gene downstream the M gene and truncating VSV G protein ([Figure 6F](#F6){ref-type="fig"}) were also adapted to rescue a recombinant VSV based HIV-1 vaccine ([@B51]).

The inherent genomic characteristics of rhabdoviruses, such as having well-defined transcription start/stop signals ([@B209]), and the ability to accommodate large inserts while retaining high level expression rates ([@B96]), together with negligible seropositivity in the human population ([@B184]) made VSV a lucrative candidate for vaccine development and as vector for a number of biomedical applications such as recombinant viral vaccines ([@B190]; [@B139]), gene delivery vectors ([@B18]), or oncolytic vectors ([@B27]) as exemplified in [Table 5](#T5){ref-type="table"}. Currently, there are a number of on-going clinical trials based on VSV^[1](#footnote1){ref-type="fn"}^, such as Phase I/II clinical trials for VSV based Ebola virus vaccines (rVSV-ZEBOV) ([@B105]).

###### 

List of some of the animal rhabdoviruses that have been reverse engineered for various medical applications.

  **Recombinant virus vaccine based on VSV**                                                                                                                                       
  ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------- ---------
  **Viral vaccines for infectious diseases**                                                                                                                                       
  Ebola virus (EBOV)                                           Ebola virus Zaire strain (ZEBOV) glycoprotein                                                                       [@B180]
  Hepatitis B virus (HBV)                                      HBV middle envelope surface protein (MS)                                                                            [@B46]
  Hepatitis C virus (HCV)                                      HCV envelope glycoproteins E1 and E2                                                                                [@B153]
  Human immunodeficiency virus (HIV)                           HIV envelope protein with its cytoplasmic domain replaced with that of the VSV glycoprotein                         [@B187]
  Influenza virus                                              H5N1 (H5 of an H5N1 highly pathogenic avian influenza virus and the N1 of the mouse-adapted H1N1 influenza virus)   [@B188]
  Severe acute respiratory syndrome (SARS)                     SARC coronavirus (CoV) spike (S) glycoprotein                                                                       [@B117]
  **Oncolytic virotherapy**                                                                                                                                                        
  Brain tumor cells                                            Chikungunya polyprotein (E3-E2-6K-E1)                                                                               [@B259]
  Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infected Cells   HTLV-1 Primary Receptors                                                                                            [@B218]
  Malignant Melanoma                                           Lymphocytic choriomeningitis virus glycoprotein                                                                     [@B124]
  Prostate cancer                                              Lymphocytic choriomeningitis virus glycoprotein                                                                     [@B228]
  **Biomedical applications**                                                                                                                                                      
  Retrograde *trans*-neuronal tracing                          Rabies virus glycoprotein                                                                                           [@B18]

Nowadays VSV is commonly considered a very successful and widely used platform for heterologous expression of more complex and interesting pharmaceuticals and biomolecules, and for the generation of (pseudo) typed eVLPs for vaccine purposes. It is expected that the availability and exploitation of enveloped plant viruses as biological particles, in analogy to VSV, will give a boost to the exploitation of plant-based production platforms for more complex (glyco)proteins.

Concluding Remarks {#S7}
==================

Plant molecular pharming has materialized as a reliable and cost-effective platform for the production of pharmaceuticals, vaccines, and biobetter products with a number of plant-produced proteins starting to be commercialized ([@B178]; [@B256]). Simultaneously, the development of viral vectors, together with agroinfection, culminated in rapid transient expression systems that successfully express high levels of large and complex pharmaceutical proteins and antimicrobial peptides ([@B75]; [@B39]; [@B174]; [@B148]; [@B141]) and enabled the production of plant-virus based VLPs against chronic and infectious diseases ([@B98]; [@B191]). However, as with their comparative systems counterparts, plant-virus based VLP(s) are inherently constrained in their ability to present complex antigens and glycoproteins. Moreover, in the case of rapidly evolving viruses, such as influenza, selective pressure will drive viral evasion of immune response induced by VLP vaccines based on few amino acids or antigens that cannot reproduce native conformational epitopes. Furthermore, attempts to produce plant-made eVLP, such as influenza HA VLP, has been so far proven successful only because of the inherent characteristics of the influenza virus HA and its ease of detachment as eVLP from plants cell surface ([@B55]); a basis for success not necessary applicable in other cases. Therefore, developments in reverse engineering inherently enveloped plant-viruses such as rhabdoviruses is expected to give plant molecular pharming a platform for a wide range of biotechnological applications, most relevant of which is expressing enveloped VLPs exposing chimeric and complex antigens.

Considering VSV as prototype, the inherent rhabdovirus characteristics of being enveloped, with defined genomic transcription units ([@B199]), genome stability ([@B236]), and an ability to stably incorporate recombinant glycoprotein into their envelope ([@B198]) make them ideal for various biotechnological applications. Plant rhabdoviruses, share such inherent characteristics, together with dispensability of the G protein for systemic plant-infection as demonstrated with SNYV ([@B238]). The G protein is required for virus entry and subsequent propagation within the arthropods vector ([@B102]), while only the carboxyl-terminal domain of the G protein, together with M protein are required for the morphogenesis and the budding of the enveloped particles ([@B212]). Hence these additional characteristics will enable large scale production of recombinant rhabdovirus based eVLP in which the (exposed) ectodomain of the G has been exchanged for another gene-of-interest (GOI) glycoprotein. Such chimeric viruses are contained within the plant and require less stringent containment controls. Similarly to VSV-recombinant design, plant rhabdovirus vector constructs can also be constructed containing a GOI at different gene positions for various expression purposes ([Figure 6](#F6){ref-type="fig"}). All these advantages together with the establishment of plant molecular pharming as cost effective and reliable production platform, make plant rhabdoviruses promising candidates in biotechnology in general and in the field of plant-made recombinant viral vaccines in specific.
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